Sign In
Buy ALNY
$291.22
-6.47 (-2.17%)
At Close: Jun 10, 2026
Alnylam (ALNY) Up as Q2 Earnings Beat on Collaboration Revenues
10:46am, Friday, 02'nd Aug 2024
Alnylam (ALNY) gains 13% on upbeat second-quarter results, beating both earnings and revenue estimates, primarily driven by higher collaboration revenues from Regeneron and strong Amvuttra sales.
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2024 Earnings Call Transcript
01:58pm, Thursday, 01'st Aug 2024
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q2 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Christine Lindenboom - SVP, IR and Corporate Communications Yvonne Greenstr
Alnylam (ALNY) Reports Q2 Earnings: What Key Metrics Have to Say
12:30pm, Thursday, 01'st Aug 2024
While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to
Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates
10:15am, Thursday, 01'st Aug 2024
Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of a loss of $0.74 per share. This compares to loss of $2.21 per share a year a
Seeking Clues to Alnylam (ALNY) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
10:21am, Tuesday, 30'th Jul 2024
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Alnylam (ALNY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the qu
Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:08am, Thursday, 25'th Jul 2024
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alnylam Stock Is a Blockbuster Biopharma In the Making
06:05am, Thursday, 18'th Jul 2024
Biopharmaceutical stock Alnylam Pharmaceuticals (NASDAQ: ALNY ) is riding a tsunami of hope that a treatment for a rare heart condition receives Food & Drug Administration approval. Although it has se
35% Surge Just the Beginning? Alnylam's Stock Poised for Massive Gains on Heart Drug Success.
06:30am, Thursday, 11'th Jul 2024
Could Alnylam Pharmaceuticals (NASDAQ: ALNY ) become a household name in 2024? At the very least, the company should be well known in the medical community.
7 Cheap Biotech Stocks With Major Upside Potential
06:00am, Tuesday, 09'th Jul 2024
Intuitively, the case for biotechnology-related investments comes across rather obviously: the concept of healthcare should be a permanent one. And because of this permanence, the expected market valu
What's Next For Alnylam Stock After A 60% Rise In A Week?
07:00am, Friday, 28'th Jun 2024
Alnylam Pharmaceuticals stock (NASDAQ: ALNY), a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, has seen a significant rise of 60% in a week. This can
Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals
10:00am, Tuesday, 25'th Jun 2024
Alnylam (ALNY) soars as its phase III study, seeking to expand Anvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy, achieves primary and all secondary endpoints.
Alnylam CEO on what is next for heart disease drug
06:40pm, Monday, 24'th Jun 2024
CNBC's Angelica Peebles and Yvonne Greenstreet, Alnylam CEO, joins 'Fast Money' to talk the companies latest heart condition drug data and what the path to approval looks like.
HELIOS-B Shines Bright And Gives Alnylam Pharmaceuticals Another Blockbuster
11:37am, Monday, 24'th Jun 2024
HELIOS-B Phase III study of Amvuttra in patients with ATTR-CM succeeded across all metrics, showing significant benefits in both the combined study population and monotherapy groups. Amvuttra showed s
Alnylam Stock Soars on Strong Results in Heart Drug Study
11:26am, Monday, 24'th Jun 2024
Shares of Alnylam Pharmaceuticals (ALNY) skyrocketed over 31% in early trading Monday after the biopharma firm announced strong results from a late-stage study of its RNA interference drug for a rare
Alnylam Pharmaceuticals reports promising heart disease trial results
11:03am, Monday, 24'th Jun 2024
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) opened more than 30% up on Monday after reporting promising results from a late-stage trial of its heart drug. Shares of the biopharmaceutical company are
